
Wockhardt Limited has informed the Exchange regarding a press release dated October 16, 2024, titled - Wockhardt files fast-acting Insulin Aspart injection (ASPARAPIDTM) with DCGI; strengthens commitment to diabetes management .
Filed with NSE ·

Wockhardt Limited has informed the Exchange regarding a press release dated October 16, 2024, titled - Wockhardt files fast-acting Insulin Aspart injection (ASPARAPIDTM) with DCGI; strengthens commitment to diabetes management .
6ix hasn’t read this filing yet.
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt